4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clerodane diterpenoids with anti-inflammatory and synergistic antibacterial activities from Tinospora crispa

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Compounds 5 and 7 exhibited nitric oxide release inhibitory activities with IC 50 values of 7.5 and 10.6 μM, respectively, and compounds 9 and 14 at the sub-MIC level significantly decreased the MIC of oxacillin against MRSA from 32.0 to 1.0 and 0.5 μg mL −1, respectively.

          Abstract

          Ten new and four known clerodane diterpenoids were isolated from the vine and leaves of Tinospora crispa. The chemical structures and absolute stereochemical configurations of all the compounds were established by spectroscopic methods and single-crystal X-ray diffraction analysis combined with electronic circular dichroism (ECD) analysis. All these compounds possess a lactone ring system except compound 10 which has a rare bridge ring between C-2 and C-20. The lactone ring in these compounds is diversely constructed between C-1 and C-18, C-6 and C-18, C-6 and C-17, C-12 and C-17, or C-15 and C-16 in the clerodane diterpenoid skeleton. All the compounds were assayed for their anti-inflammatory activities on lipopolysaccharide (LPS)-activated microglial BV-2 cells. Compounds 5 and 7 exhibited nitric oxide (NO) release inhibitory activities with IC 50 values of 7.5 and 10.6 μM respectively. In particular, compound 7 exhibited better inhibitory activity and less cytotoxicity than the positive control minocycline. Moreover, compounds 9 and 14 were found to synergize with oxacillin (OXA) against methicillin-resistant Staphylococcus aureus (MRSA). This synergy was further confirmed by checkerboard and time-killing assays. Compounds 9 and 14 at the sub-MIC level significantly decreased the MIC of OXA from 32.0 to 1.0 μg mL −1 and 0.5 μg mL −1, respectively.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: not found
          • Article: not found

          OLEX2: a complete structure solution, refinement and analysis program

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Antibacterial Activity of Silver Nanoparticles: Structural Effects

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial

              This study aimed to investigate the role of baseline levels of peripheral inflammation when testing the efficacy of antidepressant augmentation with minocycline in patients with treatment-resistant depression. We conducted a 4-week, placebo-controlled, randomised clinical trial of minocycline (200 mg/day) added to antidepressant treatment in 39 patients selected for elevated levels of serum C-reactive protein (CRP ≥ 1 mg/L), n  = 18 randomised to minocycline (M) and n  = 21 to placebo (P). The main outcome was the change in Hamilton Depression Rating Scale (HAM-D-17) score from baseline to week 4, expressed both as mean and as full or partial response, in the overall sample and after further stratification for baseline CRP≥3 mg/L. Secondary outcomes included changes in other clinical and inflammatory measures. Changes in HAM-D-17 scores and the proportion of partial responders did not differ between study arms. After stratification for CRP levels <3 mg/L (CRP − ) or ≥3 mg/L (CRP + ), CRP + /M patients showed the largest changes in HAM-D-17 scores (mean ± SD = 12.00 ± 6.45) compared with CRP - /M (2.42 ± 3.20, p  < 0.001), CRP + /P (3.50 ± 4.34, p  = 0.003) and CRP − /P (2.11 ± 3.26, p  = 0.006) patients, and the largest proportion (83.3%, p  = 0.04) of partial treatment response at week 4. The threshold point for baseline CRP to distinguish responders from non-responders to minocycline was 2.8 mg/L. Responders to minocycline had higher baseline IL-6 concentrations than non-responders ( p  = 0.03); IFNγ was significantly reduced after treatment with minocycline compared with placebo ( p  = 0.03). Our data show some evidence of efficacy of add-on treatment with minocycline in MDD patients but only in those with low-grade inflammation defined as CRP ≥3 mg/L.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                Journal
                OCFRA8
                Organic Chemistry Frontiers
                Org. Chem. Front.
                Royal Society of Chemistry (RSC)
                2052-4129
                December 06 2022
                2022
                : 9
                : 24
                : 6945-6957
                Affiliations
                [1 ]State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources/Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, People's Republic of China
                [2 ]Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou 563006, China
                Article
                10.1039/D2QO01437H
                35d8cea7-4547-4e56-9051-3d865f64b83a
                © 2022

                http://rsc.li/journals-terms-of-use

                History

                Comments

                Comment on this article